Patents by Inventor Masakazu Miyazaki
Masakazu Miyazaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11944620Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 12, 2023Date of Patent: April 2, 2024Assignee: ASTELLAS PHARMA INC.Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
-
Patent number: 11938131Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-(3-methoxy-4-4-(4-methylpiperazin-1-yl)piperidin-1-yl phenylamino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 12, 2023Date of Patent: March 26, 2024Assignee: ASTELLAS PHARMA INC.Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
-
Patent number: 11938130Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 12, 2023Date of Patent: March 26, 2024Assignee: ASTELLAS PHARMA INC.Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
-
Patent number: 11938132Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 12, 2023Date of Patent: March 26, 2024Assignee: ASTELLAS PHARMA INC.Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
-
Patent number: 11938133Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 12, 2023Date of Patent: March 26, 2024Assignee: ASTELLAS PHARMA INC.Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
-
Publication number: 20230310422Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 5, 2023Publication date: October 5, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20230301992Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 12, 2023Publication date: September 28, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20230277531Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 12, 2023Publication date: September 7, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20230277529Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 12, 2023Publication date: September 7, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20230277532Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 12, 2023Publication date: September 7, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20230277530Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 12, 2023Publication date: September 7, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20230129146Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 21, 2022Publication date: April 27, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20220152020Abstract: Provided is a pharmaceutical composition containing 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof and a sweetener for reducing the bitterness of gilteritinib, suppressing the decrease in dissolution stability of gilteritinib due to, for example, stress such as heat and/or humidity over time, and having excellent dissolution stability. The pharmaceutical composition contains gilteritinib or a pharmaceutically acceptable salt thereof, a sweetener, and sugars and/or sugar alcohols.Type: ApplicationFiled: April 2, 2020Publication date: May 19, 2022Inventors: Akihiko SASAKI, Ko TANAKA, Masakazu MIYAZAKI, Seiji TAKAE
-
Publication number: 20200383977Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-4[-4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 24, 2020Publication date: December 10, 2020Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Patent number: 10786500Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 1, 2016Date of Patent: September 29, 2020Assignee: ASTELLAS PHARMA INC.Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
-
Publication number: 20180185359Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 1, 2016Publication date: July 5, 2018Applicant: ASTELLAS PHARMA INC.Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Patent number: 9775832Abstract: Provided is a pharmaceutical composition for oral administration enabling improved solubility, improved dissolution properties, and improved oral absorbability of (2R)—N-({5-[3-(2,5-difluorophenyl)-2-(1,3-dihydro-2H-benzimidazole-2-ylidene)-3-oxopropanoyl]-2-fluorophenyl}sulfonyl)-2-hydroxypropane imide amide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, as well as size reduction. The pharmaceutical composition for oral administration contains an amorphous form of compound A or its pharmaceutically acceptable salt, and a polymer.Type: GrantFiled: June 24, 2015Date of Patent: October 3, 2017Assignee: ASTELLAS PHARMA INC.Inventors: Hiroyuki Kojima, Masakazu Miyazaki, Mare Nishiura, Takashi Nishizato
-
Publication number: 20170143678Abstract: Provided is a pharmaceutical composition for oral administration enabling improved solubility, improved dissolution properties, and improved oral absorbability of (2R)—N-({5-[3-(2,5-difluorophenyl)-2-(1,3-dihydro-2H-benzimidazole-2-ylidene)-3-oxopropanoyl]-2-fluorophenyl}sulfonyl)-2-hydroxypropane imide amide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, as well as size reduction. The pharmaceutical composition for oral administration contains an amorphous form of compound A or its pharmaceutically acceptable salt, and a polymer.Type: ApplicationFiled: June 24, 2015Publication date: May 25, 2017Applicant: ASTELLAS PHARMA INC.Inventors: Hiroyuki KOJIMA, MASAKAZU MIYAZAKI, MARE NISHIURA, TAKASHI NISHIZATO
-
Patent number: 5636312Abstract: A video image mixing apparatus which can prevent a fluctuation of a mixed video image by a mixed video signal in the case where a playback video signal obtained by playing a recording medium in a special playing mode and a graphics video signal. When a discontinuity of the phase of a color burst signal in the playback video signal obtained by playing the recording medium is detected, the playback video signal and the graphics video signal are delayed by a predetermined time period and the delayed signals are mixed subsequently, thereby keeping the phases of chroma signals of the playback video signal and graphics video signal equal even in a special playing mode such as a still image reproducing mode or the like. In another embodiment, the mixed video signal of the playback video signal and graphics video signal is delayed by a predetermined time and is generated.Type: GrantFiled: December 17, 1993Date of Patent: June 3, 1997Assignee: Pioneer Electronic CorporationInventors: Manabu Okamoto, Takashi Yoshimi, Hiroyasu Matsuura, Noriyoshi Takeya, Hitoshi Yamazaki, Masakazu Miyazaki, Hirofumi Matoba
-
Patent number: D537778Type: GrantFiled: November 8, 2005Date of Patent: March 6, 2007Assignee: TDK CorporationInventor: Masakazu Miyazaki